Alice Rossi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Anti-inflammatory therapies from bedside to bench: Frameworks to support preclinical development.

Anti-inflammatory therapies from bedside to bench: Frameworks to support preclinical development.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 29, 2025

Dual-action thioarylamide-based small molecules to target drug-resistant bacteria and chronic inflammation.

Dual-action thioarylamide-based small molecules to target drug-resistant bacteria and chronic inflammation.

Journal: iScience

Published: May 13, 2025

Valorization of Local Agricultural Byproducts for the Development of Functional Oat-Based Milk Formulations.

Valorization of Local Agricultural Byproducts for the Development of Functional Oat-Based Milk Formulations.

Journal: Foods (Basel, Switzerland)

Published: March 27, 2025

Prevalence of Mitral Annular Disjunction at Cardiac MRI: Results from a Multicenter Registry.

Prevalence of Mitral Annular Disjunction at Cardiac MRI: Results from a Multicenter Registry.

Journal: Radiology. Cardiothoracic imaging

Published: December 19, 2024

Assessing the Potential of N-Butyl-l-deoxynojirimycin (l-NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent.

Assessing the Potential of N-Butyl-l-deoxynojirimycin (l-NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent.

Journal: ACS pharmacology & translational science

Published: January 26, 2024

Improving the Predictive Value of Preclinical Mouse Models of Pseudomonas aeruginosa Respiratory Infection to Evaluate Antibiotic Efficacy.

Improving the Predictive Value of Preclinical Mouse Models of Pseudomonas aeruginosa Respiratory Infection to Evaluate Antibiotic Efficacy.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 11, 2023

New TMA (4,6,4'-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease.

New TMA (4,6,4'-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease.

Journal: International journal of molecular sciences

Published: September 27, 2022

Efficacy of selective histone deacetylase 6 inhibition in mouse models of Pseudomonas aeruginosa infection: A new glimpse for reducing inflammation and infection in cystic fibrosis.

Efficacy of selective histone deacetylase 6 inhibition in mouse models of Pseudomonas aeruginosa infection: A new glimpse for reducing inflammation and infection in cystic fibrosis.

Journal: European journal of pharmacology

Published: August 06, 2022

Pamoic acid is an inhibitor of HMGB1·CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia.

Pamoic acid is an inhibitor of HMGB1·CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia.

Journal: Molecular medicine (Cambridge, Mass.)

Published: April 08, 2022

β-sitosterol ameliorates inflammation and Pseudomonas aeruginosa lung infection in a mouse model.

β-sitosterol ameliorates inflammation and Pseudomonas aeruginosa lung infection in a mouse model.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 22, 2022

Lung and Gut Microbiota Changes Associated with Pseudomonas aeruginosa Infection in Mouse Models of Cystic Fibrosis.

Lung and Gut Microbiota Changes Associated with Pseudomonas aeruginosa Infection in Mouse Models of Cystic Fibrosis.

Journal: International journal of molecular sciences

Published: September 30, 2021

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis.

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis.

Journal: Frontiers in pharmacology

Published: April 29, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026